Quote this publication Share Print

COSENTYX (secukinumab), anti-interleukin immunosuppressant

DERMATOLOGY - New medicinal product
Opinions on drugs - Posted on Apr 06 2016

Reason for request

Inclusion

Minor improvement in the treatment of chronic severe plaque psoriasis by comparison with STELARA.

  • COSENTYX has Marketing Authorisation in the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
  • Because of uncertainties about its long-term safety, it should be reserved for adults with chronic severe plaque psoriasis who have failed to respond to or tolerate, or present contraindications to, at least two systemic treatments such as methotrexate, acitretin, ciclosporin and phototherapy.
  • Its efficacy in terms of PASI 90 response is superior to STELARA, which is an interleukin IL-12 and IL-23 inhibitor.



 


Clinical Benefit

Substantial

-

Insufficient

Clinical Added Value

minor

-


Therapeutic use

-

-

 

Contact Us

Évaluation des médicaments